- Home
- CANF vs JCSE Comparison
CANF vs JCSE Comparison
Compare CANF & JCSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- JCSE
- Stock Information
- Founded
- CANF 1994
- JCSE 1999
- Country
- CANF Israel
- JCSE Singapore
- Employees
- CANF N/A
- JCSE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- JCSE Miscellaneous manufacturing industries
- Sector
- CANF Health Care
- JCSE Consumer Discretionary
- Exchange
- CANF Nasdaq
- JCSE Nasdaq
- Market Cap
- CANF 9.4M
- JCSE 7.6M
- IPO Year
- CANF N/A
- JCSE 2022
- Fundamental
- Price
- CANF $1.54
- JCSE $1.46
- Analyst Decision
- CANF Strong Buy
- JCSE
- Analyst Count
- CANF 2
- JCSE 0
- Target Price
- CANF $14.00
- JCSE N/A
- AVG Volume (30 Days)
- CANF 117.2K
- JCSE 34.8K
- Earning Date
- CANF 02-03-2025
- JCSE 10-30-2024
- Dividend Yield
- CANF N/A
- JCSE 12.16%
- EPS Growth
- CANF N/A
- JCSE N/A
- EPS
- CANF N/A
- JCSE 0.12
- Revenue
- CANF $667,000.00
- JCSE $14,723,999.00
- Revenue This Year
- CANF $409.56
- JCSE N/A
- Revenue Next Year
- CANF N/A
- JCSE N/A
- P/E Ratio
- CANF N/A
- JCSE $12.07
- Revenue Growth
- CANF N/A
- JCSE N/A
- 52 Week Low
- CANF $1.29
- JCSE $0.60
- 52 Week High
- CANF $4.69
- JCSE $2.39
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- JCSE 52.84
- Support Level
- CANF $1.55
- JCSE $1.37
- Resistance Level
- CANF $1.64
- JCSE $1.58
- Average True Range (ATR)
- CANF 0.10
- JCSE 0.09
- MACD
- CANF 0.01
- JCSE 0.01
- Stochastic Oscillator
- CANF 11.76
- JCSE 61.29
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About JCSE JE Cleantech Holdings Limited
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The product lives of its cleaning systems and other equipment range from two to ten years. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. It derives a majority of its revenue from Singapore.